Biobanking in Genomic Medicine

Jane H. Zhou, MD; Aysegul A. Sahin, MD; Jeffrey N. Myers, MD, PhD

● **Context.**—Genomic medicine requires the identification of biomarkers and therapeutic targets, which in turn, requires high-quality biospecimens. Achieving high-quality biospecimens requires implementing standard operating procedures to control the variations of preanalytic variables in biobanking. Currently, most biobanks do not control the variations of preanalytic variables when collecting, processing, and storing their biospecimens. However, those variations have been shown to affect the quality of biospecimens and gene expression profiling.

Objective.—To identify evidence-based preanalytic parameters that can be applied and those parameters that need further study.

Data Sources.—We searched the Biospecimen Research and PubMed databases using defined key words. We retrieved and reviewed 212 articles obtained through those searches. We included 58 articles (27%) according to our inclusion and exclusion criteria for this review.

Conclusion.—Preanalytic variables in biobanking can degrade the quality of biospecimens and alter gene expression profiling. Variables that require further study include the effect of surgical manipulation; the effect of warm ischemia; the allowable duration of delayed specimen processing; the optimal type, duration, and temperature of preservation and fixation; and the optimal storage duration of formalin-fixed, paraffin embedded specimens in a fit-for-purpose approach.

(*Arch Pathol Lab Med.* 2015;139:812–818; doi: 10.5858/arpa.2014-0261-RA)

Genomic medicine treats diseases based on prognostic and predictive biomarkers and therapeutic targets identified through DNA sequence analysis and gene expression profiling of diseased tissues—that is, through biospecimens. To reflect the true genomic changes of disease, gene expression profiling requires high-quality biospecimens, which are those that most closely resemble the tissue before its removal from the human body. To achieve that goal, biobanks need to integrate systems of consenting, annotating, collecting, processing, storing, and distributing biospecimens using unified standard operating procedures (SOPs).

Currently, both within and across institutions, unified SOPs in biobanking are lacking. Because of the lack of unified SOPs, the preanalytic variables in biobanking are not well controlled. However, fluctuations in those variables have been shown to affect the quality of biospecimens and gene expression profiling. Furthermore, the lack of unified SOPs in biobanking has in part led to irreproducible experimental results,[1] difficulty in comparing and validating research findings,[2] and investigator's concerns about research findings because of the poor quality of biospecimens.[3] For example, a survey report by Prinz et al[4] showed that almost two-thirds of the published data on therapeutic targets could not be reproduced. Reports by the RAND Corporation[5] (Santa Monica, California) indicated that more than 300 million biospecimens were collected and stored in various institutions in the United States in 1999 alone, but the lack of unified SOPs in consenting, annotating, collecting, processing, and storing made it difficult to compare and validate test results using those biospecimens.[6] The lack of proper consent and standard annotation of biospecimens has limited the value of that vast resource. However, the government and various organizations both in the United States and abroad have published guidelines and recommendations for biobanking. The Office for Human Research Protections of the Department of Health & Human Services (Washington, DC) and the National Cancer Institute (Bethesda, Maryland) has issued recommendations on legal and ethical aspects of consenting for biobanking.[7,8] The National Cancer Institute, the College of American Pathologists (Northfield, Illinois) Diagnostic Intelligence and Health Information Technology Committee, and the International Society for Biological and Environmental Repositories (ISBER; Vancouver, British Columbia, Canada) have developed guidelines on annotation of biospecimens.[9–11] Furthermore, both the National Cancer Institute and ISBER have published guidelines on best practices of biobanking.[8,12] However, those guidelines do not provide the specific parameters that are needed to establish SOPs for each variable. Defining specific parameters for each variable would require evidence-based biospecimen science.

Here, we reviewed studies of preanalytic variables in the collecting, processing and storing biospecimens on their quality and their effect on gene expression profiling using DNA or RNA as analytes. The variables included warm

Biobanking in Genomic Medicine—Zhou et al

ischemia, surgical manipulation, cold ischemia/delayed specimen processing, preservation at low temperature, preservative and fixative types, preservation and fixation duration and temperature, freeze-thaw cycles, and storage duration. Our goal in this review is to identify evidence-based parameters on preanalytic variables that can be used now and those that require further study to improve the quality of biospecimens, and thereby, to enhance the accurate identification of biomarkers and therapeutic targets in genomic medicine.

REVIEW OF THE LITERATURE: INCLUSION AND EXCLUSION CRITERIA

We searched the Biospecimen Research Database (http://biospecimens.cancer.gov/brd) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) for published literature. The Biospecimen Research Database, a freely accessible database of the National Institutes of Health (Bethesda, Maryland), contains "peer-reviewed literature pertinent to the field of human biospecimen science." One can search the database using key terms within the categories of analyte, technology platform, type of biospecimen, and normal or cancerous tissue. More than 2000 published articles were collected in the database as June 1, 2014. The database is periodically updated, although the frequency of that update is not specified. We searched this database using the terms *DNA sequencing, polymerase chain reaction* (PCR), *real-time quantitative polymerase chain reaction, real-time quantitative reverse transcriptase polymerase chain reaction* (qRT-PCR), *reverse-transcriptase polymerase chain reaction* (RT-PCR), *single nucleotide polymorphism assay*. We used the terms *biobank, biorepository*, and *biospecimen* for the PubMed (National Center for Biotechnology Information, Bethesda, Maryland) search. We did not include search terms to retrieve studies using immunohistochemistry or in situ hybridization in this review because those topics have been recently reviewed elsewhere.[13,14] We retrieved and reviewed 212 articles obtained through these searches. We then excluded articles that met one or more of the following criteria: (1) studies that were published before 1998, (2) studies that did not use tissue from the same specimen for comparison, (3) studies that used assays or reagents that were developed or used only in that laboratory or institution, (4) studies that used nonhuman tissue specimens, (5) studies that did not specify the actual changes, and (6) studies that compared different commercial DNA or RNA extraction kits. We included 58 articles (27%) published between January 1998 and April 2014 in this review.

TISSUE SPECIMENS

Table 1 summarizes the characteristics of the studies that used tissue specimens.

Warm Ischemia

Warm ischemia, which occurs when blood vessels to an organ are ligated during surgery, can affect gene expression profiling without affecting RNA quality. One study[15] compared the gene expression profiles of specimens collected at the intraoperative exposure of the prostate (in situ) with those of specimens collected immediately after resection (ex vivo). The level of mRNA expression in 8 (*EGR1, p21, KRT17, PIM1, S100P, TNFRSF, WFDC2,* and *TRIM29*) of 91 cancer-associated genes (9%) increased at least 2-fold, even though the RNA quality measured by the 28S to 18S ratio was not affected.[15] Likewise, using lung cancer specimens collected at the chest opening and immediately after resection, 1% of the genes (eg, *TNF, IL6,* and *FOS*) differed by more than 2-fold.[16] Therefore, to avoid the effect of warm ischemia on gene expression profiling, collecting biospecimens preoperatively has been suggested as the optimal method.[15]

Surgical Manipulation

The extent to which surgical manipulation affects gene expression profiling needs further investigation. A study[17] of surgical manipulation compared radical retropubic prostatectomy specimens collected immediately after midline incision (in situ) with those collected immediately after surgical resection (ex vivo). The expression levels of 41 transcripts increased by 2-fold or more; those transcripts included genes for acute-phase response proteins (*IER2* and *JUNB*) and regulators of cell proliferation (*p21Cip1* and *KLF6*). However, the increased gene expression may have been due to surgical manipulation and warm ischemia rather than surgical manipulation per se. Nevertheless, another study found that the greatest change in gene expression was from the time of intraoperative exposure of the prostate to the ligation of the dorsal vein complexes,[15] suggesting an effect of surgical manipulation. In contrast, the gene expression profile did not differ in specimens collected using 2 types of prostatectomy procedures (robot-assisted laparoscopic prostatectomy and radical retropubic prostatectomy), although the protein levels differed significantly on tissue microarrays by immunohistochemical analysis.[18] Overall, these findings suggest that to study the effect of surgical manipulation, the confounding effect of warm ischemia needs to be controlled.

Cold Ischemia and Delayed Specimen Processing

Cold ischemia occurs when tissues or organs within or removed from the human body are allowed to cool before being preserved. We combined the reviews of cold ischemia and delayed specimen processing because a definitive time point for distinguishing between them is difficult to determine from the literature.

Cold ischemia/delayed specimen processing can affect the quality of nucleic acid and the expression of genes and proteins. The expression levels of 5% of genes in lung cancer altered at least 2-fold after a 30-minute processing delay.[16] Similarly, mRNA expression differed more than 2-fold in 2.3% of the genes in colorectal cancer after a 30- to 120-minute processing delay, and the changes started after only 15-minute processing delay.[19] Likewise, the number of altered genes in breast cancer increased with the increasing duration of processing delay, from 0.76% of the genes after a 2-hour delay to 4.1% after a 24-hour delay.[20] A biobank study[21] compared gene expression profiling in biospecimens before and after the deployment of SOPs, which resulted in more than twice the number of biospecimens cryopreserved within 30 minutes. The study found that the mRNA expression of *c-MYC* and *ER* and the estrogen receptor protein level decreased with increasing duration of processing delay,[21] demonstrating that unified SOPs in biobanking are needed to ensure meaningful comparison and validation of test results. However, others[22,23] have found that the changes in RNA quality and gene expression from delayed specimen

Table 1. Characteristics of Studies Using Tissue Specimens

Preanalytic Variable	Source, y	Specimen Processing
Warm ischemia	Schlomm et al,[15] 2008	At organ exposure and immediately after surgery
	Freidin et al,[16] 2012	At chest opening and immediately after surgery
Surgical manipulation	Schlomm et al,[15] 2008	At organ exposure and at blood vessel ligation during surgery
	Lin et al,[17] 2006	After induction of anesthesia and immediately after surgery
	Ricciardelli et al,[18] 2010	Two types of procedures
Cold ischemia or delayed processing	Freidin et al,[16] 2012	Immediately after surgery and after 30-min delay
	Bray et al,[19] 2010	Presurgery biopsies preserved at 15, 30, 60, and 120 min
	De Cecco et al,[20] 2009	Immediately after surgery and at 2, 6, and 24 h
	Barnes et al,[21] 2008	<30, 31–60, 61–120, and >120 min
	Blackhall et al,[22] 2004	Immediately after surgery and at 5, 10, 15, 20, 30, 40, 50, 60, and 120 min
	van Maldegem et al,[23] 2008	At 0 to 48 h
Preservation at low temperature	Steu et al,[24] 2008	Snap-freezing methods
	Sewart et al,[25] 2009	4°C overnight
Preservatives or fixatives	van Maldegem et al,[23] 2008	Formalin-fixation time
	Macabeo-Ong et al,[27] 2002	Formalin-fixation time
	Moelans et al,[28] 2011	Alcohol fixatives
	Gillespie et al,[29] 2002	Alcohol fixatives
	Antonov et al,[30] 2005	RNALater (Qiagen, Germantown, Maryland)
	Johnsen et al,[31] 2010	RNALater (Ambion, Applied Biosystems, Foster City, California)
	Lawson et al,[32] 2010	RNALater (Ambion, Austin, Texas)
	Freidin et al,[16] 2012	RNALater (Qiagen, Germantown, Maryland)
	Bray et al,[19] 2010	RNALater (Qiagen, Crawley, West Sussex, United Kingdom)
	Paska et al,[33] 2004	Formalin, acetone, RNALater (R 0901, Sigma, St Louis, Missouri)
Freeze-thaw cycles	Johnsen et al,[31] 2010	Freeze-thaw cycles
	Botling et al,[34] 2009	Freeze-thaw cycles
FFPE	Christensen et al,[35] 2006	FFPE versus snap frozen
	Gallegos et al,[37] 2007	FFPE versus snap frozen
	Talaulikar et al,[38] 2008	FFPE versus snap frozen
	Verhoest et al,[39] 2012	FFPE versus snap frozen
	Solassol et al,[40] 2011	FFPE versus snap frozen
	Williams et al,[41] 1999	FFPE versus snap frozen
	Kerick et al,[42] 2011	FFPE versus snap frozen
	Menon et al,[43] 2012	FFPE versus snap frozen
	Schweiger et al,[44] 2009	FFPE versus snap frozen
	Lips et al,[45] 2005	FFPE versus snap frozen
	Thompson et al,[46] 2005	FFPE versus snap frozen
	Glud et al,[47] 2009	FFPE versus snap frozen
Storage duration	Freidin et al,[16] 2012	2-y-old FFPE
	Turashvili et al,[48] 2012	>15-y-old FFPE
	Siebolts et al,[49] 2009	7-, 17-, 27-y-old FFPE
	Szafranska et al,[50] 2008	1-, 7-, 11-y-old FFPE

Abbreviations: BCC, basal cell carcinoma; FFPE, formalin fixation and paraffin embedding; qPCR, quantitative polymerase chain reaction; qRT-PCR, quantitative reverse transcriptase-PCR; RCC, renal cell carcinoma.

processing are insignificant. These findings may be explained by using the mean of the changes of gene expressions,[21] because the changes can be either increased or decreased in different genes or with a small sample size.[22] Further study of the effect of processing delay on gene expression profiling is warranted. Nevertheless, these findings suggest that delayed specimen processing can be a confounding factor in the expression of genes and proteins and that standardizing the duration of processing delay could minimize the variations in gene expression profiling.

Preservation at Low Temperature

Various fast-freeze methods have been used to preserve fresh biospecimens, including snap-freezing specimens in liquid nitrogen, embedding specimens in optimal cutting-temperature medium with immersion in –80°C isopentane, and freezing specimens using the carbon dioxide quick-freeze method. All these techniques yielded similar quantities of nucleic acids and proteins and had similar PCR and RT-PCR performance,[24] suggesting that results obtained using biospecimens preserved with these freezing methods can be meaningfully compared and validated.

On the other hand, preserving fresh tissue specimens at 4°C overnight yielded nucleic acids and protein of similar quality to that from snap-frozen specimens,[25] suggesting that fresh specimens can be kept at 4°C if a short delay in processing is anticipated.

Preservatives, Fixatives, Duration, and Temperature of Preservation and Fixation

Optimal fixation of biospecimens depends on 3 variables at a fixed temperature, namely, tissue thickness, the ratio of tissue to fixative volume, and fixation time.[26] Formalin fixation of biospecimens leads to fragmentation of nucleic acids.[23,27,28] Hewitt et al[26] found that the length of fixation time, when the other variables were controlled, affects the quality of nucleic acids. They have recommended fixation time of 6 to 18 hours for biopsy specimens and 12 to 36 hours for surgical specimens to ensure the quality of nucleic

Table 1. Extended

Tissue Type	Profiling Platform
Prostate	Gene Analyzer 7900 (Applied Biosystems, Darmstadt, Germany)
Lung	Human WG6 array (Illumina, Inc, San Diego, California)
Prostate	Gene Analyzer 7900 (Applied Biosystems Darmstadt, Germany)
Prostate	GenePix 4000B (Axon Instruments, Foster City, California)
Prostate	Real-time qPCR (Bio-Rad, Ontario, Ontario, Canada)
	Human WG6 array (Illumina)
Colorectum	Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, California); ABI prism 7700 (Applied Biosystems, Warrington, Cheshire, United Kingdom)
Breast	3DNA Submicro Oligo Expression Array (Genisphere, Montvala, New Jersey); ABI PRISM 7700 (Applied Biosystems, Foster City, California)
Breast	qRT-PCR (not specified)
Lung	GenePix 4000 (Axon)
Liver and ovary	qRT-PCR (not specified)
Various tumor tissues	qRT-PCR (not specified)
Breast	qRT-PCR (not specified)
Liver and ovary	qRT-PCR (not specified)
Oral cancer	ABI 7700 Prism (PE Biosystems, Foster City, California)
Various tissues	ABI 3730 (Applied Biosystems, Foster City, California)
Prostate and kidney	PCR, qRT-PCR (not specified)
Breast	qRT-PCR (Applied Biosystems, Foster City, California)
Adrenal tumors	Real-time PCR (Agilent Technologies, Waldbronn, Germany)
Lung	2100 Bioanalyser (Agilent Technologies, Rockville, Maryland)
Lung	Human WG6 array (Illumina)
Colorectum	ABI prism 7700 (Applied Biosystems, Warrington, Cheshire, United Kingdom)
Endometrial tissue	170-8740 iCycler (Bio-Rad)
Adrenal tumors	Real-time PCR (Agilent Technologies, Waldbronn, Germany)
Tonsil tissue	ABI PRISM 7000HT (Applied Biosystems, Foster City, California)
T cell lymphoma tissue	ABI 310 (Applied Biosystems, Foster City, California)
Lung	ABI PRISM 3100 (Applied Biosystems, Foster City, California)
Bone marrow	Real-time PCR (ROCHE, Mannheim, Germany)
RCC	ABI PRISM 3130 (Applied Biosystems, Foster City, California)
Colorectum	ABI PRISM 3100 (Applied Biosystems, Foster City, California)
BCC	Direct DNA sequencing (Amersham Pharmacia Biotech, Uppsala, Sweden)
Prostate	Genome Analyzer IIx (Illumina)
Prostate	SOLiD4 (Life Technologies, Grand Island, New York)
Breast	Genome Analyzer (Illumina)
Colorectum	BeadArrays (Illumina)
Serous ovarian cancer	GeneChip Human Mapping 10K Array (Affymetrix, Santa Clara, California)
Melanocytic nevi	qRT-PCR (Applied Biosystems, Foster City, California)
Lung	Human WG6 array (Illumina)
Colon, myometrium, liver	PCR, qRT-PCR (Bio-Rad; Invitrogen, Ontario, Canada)
Lymph node	qRT-PCR (Applied Biosystems, Foster City, California)
Colon, myometrium, B-cell lymphoma	qRT-PCR (Applied Biosystems, Foster City, California)

acids. Others have suggested that 8 to 16 hours of formalin fixation at ambient temperature is optimal.[23]

Specimens fixed using 70% ethanol or alcohol-based, noncross-linking fixatives yielded a higher quality of nucleic acids and better PCR performance than did those fixed with formalin,[28,29] indicating that alcohol-based fixatives can be a useful alternative to formalin.

RNALater, the newer tissue preservative, may be a better choice than formalin fixation or even snap freezing for preserving tissue for RNA studies. Tissue specimens collected into RNALater (Ambion, Austin, Texas; Ambion, Foster City, California; Qiagen, Germantown, Maryland; Qiagen, Crawley, West Sussex, United Kingdom) before being snap frozen or stored at 4°C yielded better-quality RNA and gene expression profiling than did matched, non-RNALater, snap-frozen specimens or formalin-fixed, paraffin-embedded (FFPE) specimens.[16,19,30–32] However, other researchers[33] have not found a difference in the length of the amplicons among specimens that had been preserved in RNALater (R 0901, Sigma Company, St Louis, Missouri), acetone (00341-10-65, Reanal, Budapest, Hungary), or

formalin. These findings suggest that the types of preservatives and fixatives as well as the duration of preservation and fixation need to be further studied and standardized to ensure the accuracy of gene expression profiling.

Freeze-Thaw Cycles

Freeze-thaw cycles can affect the quality of RNA and alter gene expression profiling, phosphoprotein levels, and enzymatic activity.[31,34] These effects depend more on the total thaw time at ambient temperature than on the number of freeze-thaw cycles. A total thaw time of less than 30 minutes at ambient temperature did not affect RNA quality, regardless of the number of freeze-thaw cycles, and any changes in gene expression corresponded to the degradation of RNA.[34] In addition, preserving specimens in RNALater (Ambion, Foster City, California) alleviated the effect of thawing on RNA quality.[31,34] These findings suggest that degradation of RNA occurs primarily at ambient temperature and that it takes about 30 minutes to degrade significantly to affect gene expression.

Formalin Fixation and Paraffin Embedding

Formalin fixation and paraffin embedding, the most commonly used method of processing biospecimens, involves many variables. Hewitt et al[26] provided a good review and recommendations on standardizing the variables. FFPE specimens yield a lower proportion of amplifiable nucleic acids due to fragmentation, and higher false-negative and false-positive rates of mutation detection than are found in matched snap-frozen specimens.[35–39]

Gallegos et al[37] compared the success rate of PCR amplification using genomic DNA extracted from paired FFPE and snap-frozen lung-cancer specimens. They amplified *EGFR* exons 18 to 21 and *KRAS* exons 1 and 2 and found that 100% of snap-frozen specimens were amplified, whereas the success rate of amplification in FFPE specimens varied from 19% to 72% (median, 43.5%), with increased success rates in shorter amplicons (success rate increased from 19% to 61% by reducing the amplicon size from 295 base pairs [bp] to 235 bp). Another study[40] compared the mutation-detection rate of *KRAS* exon 2 in paired frozen and FFPE colorectal-cancer specimens. The discordant rate between frozen and FFPE specimens was 9% and 12% using high-resolution melting analysis and direct DNA sequencing, respectively. Likewise, false-positive rates of 10.5% and false-negative rates of 28.9% were found for *VHL* mutations of clear cell renal cell carcinoma using FFPE specimens.[39] In detecting gene rearrangement of T-cell receptor γ, the discordant rate between frozen and FFPE specimens was 32%.[35] Furthermore, FFPE specimens for solid-phase, direct DNA sequencing resulted in one false mutation per 500 bases.[41] The false mutations caused by FFPE were primarily C>T or G>A transitions.[40,41] However, the high false-positive and false-negative mutation rates from FFPE can be overcome using a high depth of coverage with next-generation sequencing technologies.[42–44] Overall, a concordance of gene expression profiling between FFPE and snap-frozen specimens can be achieved in amplicons shorter than 200 bases.[33,37]

In contrast, array-based genotyping platforms produced comparable results for copy number alteration, single nucleotide variation, and loss of heterozygosity between FFPE and snap-frozen specimens.[45,46] In addition, FFPE specimens were well correlated ($r = 0.80$) with snap-frozen specimens in microRNA microarray expression profiling.[47] Nevertheless, standardization of the process will reduce the variability of FFPE specimens, making the most-available, feasible, and economically efficient FFPE specimens an invaluable resource.

Storage Duration and Temperature

The storage duration of FFPE specimens can affect the quality of nucleic acids and gene expression profiling, but the effect is less on microRNA. When 2-year-old FFPE specimens were compared with matched non-FFPE specimens, the gene signals above the backgrounds were reduced 4-fold.[16] The FFPE specimens stored for 15 years failed RT-PCR amplification.[48] The FFPE specimens stored for 7 years, however, had not significantly altered microRNA expression,[49] although a gradual loss of expression was found in those microRNAs that were expressed at low levels and in older (11-year-old) specimens.[50] Therefore, aged FFPE specimens that are not fit for RNA or DNA studies may still be fit for microRNA studies. Future studies should

investigate the age parameters in this fit-for-purpose approach. Furthermore, reporting the age of FFPE specimens in gene expression profiling may improve the comparison and validation of results.

Whether the temperature and humidity of FFPE storage facilities affect gene expression profiling is unknown. The studies we reviewed did not specify the temperature or humidity of these facilities. The National Cancer Institute's best-practices guidelines recommend that FFPE specimens be stored at a temperature below 80°F (27°C), with humidity and pest control.[8]

BLOOD SPECIMENS

Table 2 summarizes the characteristics of the studies that used blood specimens.

Storage Duration at Ambient Temperature

Blood specimens are routinely collected in ethylenediaminetetraacetic acid (EDTA) or heparinized tubes. Prolonged storage of blood specimens in those tubes can affect gene expression profiling in a time-dependent manner. Storage of blood specimens in EDTA tubes (Vacutainer system, Becton, Dickinson, and Company, Heidelberg, Germany) at ambient temperature significantly altered the expression of β-actin, cytokeratin-19, *GAPDH*, *HER2*, and *EGFR*. The time interval required to reach an effect differed for each gene, with a significant decrease in the expression of cytokeratin-19 and *HER2* after 4 hours, β-actin after 6 hours, *GAPDH* after 24 hours, and a significant increase in the expression of *EGFR* after 24 hours.[51] However, another study[52] of blood specimens in EDTA tubes (Vacutainer, Becton, Dickinson, and Company, Plymouth, Devon, United Kingdom) at room temperature with different time intervals using qRT-PCR for *GAPDH* found that the threshold cycle values increased at 24 and 30 hours, but the differences were not statistically significant. Yet, storage of blood specimens for 48 hours or longer at ambient temperature resulted in splicing variants of *PTEN*,[53] and the loss of exon 20 of the *ATM* gene.[54] Moreover, another study found that 7-day storage at ambient temperature elevated the expression of *IL-6* and *TNFα* 20-fold.[55] However, detection of the *BCR/ABL* fusion transcript did not differ in peripheral blood and bone marrow aspirate specimens stored at ambient temperature for up to 96 hours.[56] These findings indicate that the effect of storage duration at ambient temperature on gene expression profiling is dependent on specific genes or the mutation type, suggesting that every effort should be made to minimize delay in specimen processing. Unified SOPs to standardize the time interval of blood specimen processing would minimize the variations of test results both within and across institutions.

PAXgene Collection Tubes

Blood specimens collected in PAXgene tubes had higher RNA quality and less variation in gene expression profiling than did those collected in EDTA tubes.[57,58] However, long-term storage of blood specimens in PAXgene tubes can degrade RNA quality. Kim et al[59] suggested that blood specimens collected in PAXgene tubes (PreAnalytiX, Qiagen, Valencia, California) should not exceed 1 day at ambient temperature, 4 days at 4°C, or 3 months at −20°C. Another study[60] showed that the storage duration and

Table 2. Characteristics of Studies Using Blood Specimens

Preanalytic Variable	Source, y	Specimen Processing	Profiling Platform
Storage duration at ambient temperature	Benoy et al,[51] 2006	0, 1, 2, 4, 6, 24, 48, and 72 h	ABI Prism 7700 (Applied Biosystems, Foster City, California)
	Palmirotta et al,[52] 2012	0, 3, 6, 10, 24, and 30 h	Gene Amp PCR System 9700 (Applied Biosystems, Foster City, California)
	Liu et al,[53] 2010	0 and 48 h	ABI 373A (Applied Biosystems, Foster City, California)
	Birrell et al,[54] 2001	<2 h to 3 d	ABI PRISM BigDye Terminator (Perkin-Elmer, Akron, Ohio)
	Pahl et al,[55] 2002	0–7 d	ABI PRISM 7700 (Applied Biosystems, Weiterstadt, Germany)
	Schoch et al,[56] 2001	0, 48, and 96 h	qRT-PCR (not specified)
	Gunther et al,[57] 2012	Immediately and after 2 h	ABI PRISM 7900 (Life Technologies, Grand Island, New York)
	Müller et al,[58] 2002	After 2 and 72 h	qRT-PCR (ROCHE Diagnostics, Mannheim, Germany)
	Kim et al,[59] 2007	1–2 d at AT, 1–40 d at 4°C, 98–194 d at −20°C	GeneChip (Affymetrix, Santa Clara, California)
	Thach et al,[60] 2003	2 h at AT, isolate RNA; store at −80°C versus 9 h at AT, freeze at −20°C for 6 d, isolate RNA	RT-PCR (Invitrogen/Life)
PAXgene tubes	Gunther et al,[57] 2012	PAXgene tube versus EDTA tube (PreAnalytixX, Qiagen, Valencia, California; Vacutainer, Becton, Dickinson, and Company, Heidelberg, Germany)	ABI PRISM 7900 (Life Technologies)
	Müller et al,[58] 2002	PAXgene tube versus EDTA tube (PreAnalytix, Qiagen; Vacutainer, Becton Dickinson)	qRT-PCR (ROCHE)

Abbreviations: AT, ambient temperature; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.

temperature of blood specimens in PAXgene tubes (Pre-Analytix, Qiagen, Valencia, California) contributed to 0.09% of the variation in RNA expression. Nevertheless, the evidence suggests that storage duration and temperature, as well as the type of collection tubes for blood specimens, should be standardized and reported to ensure the accuracy of results.

CONCLUSIONS AND FUTURE PERSPECTIVES

Preanalytic variables in biobanking affect not only the quality of nucleic acid but also gene expression profiling. To ensure the accuracy of test results and to validate those results, implementing unified SOPs in biobanking to control those variables becomes imperative in the era of genomic medicine.

Further studies are needed to determine the effect of surgical manipulation on gene expression profiling, accounting for the confounding factors of warm ischemia; the allowable duration of delayed specimen processing; the optimal type, duration, and temperature of preservation and fixation; and the optimal storage duration of FFPE specimens in a fit-for-purpose approach.

References

1. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009 biospecimen research network symposium: advancing cancer research through biospecimen science. *Cancer Res.* 2009;69(17):6770–6772.

2. Compton C. Getting to personalized cancer medicine: taking out the garbage. *Cancer.* 2007;110(8):1641–1643.

3. Massett HA, Atkinson NL, Weber D, et al. Assessing the need for a standardized cancer human biobank (caHUB): findings from a national survey with cancer researchers. *J Natl Cancer Inst Monogr.* 2011;2011(42):8–15.

4. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? *Nat Rev Drug Discov.* 2011;10(9): 712.

5. Eiseman E, Haga S. Handbook of Human Tissue Sources: A National Resource of Human Tissue Samples. Santa Monica, CA: RAND Corporation; 1999: xxvii, 251 p.

6. Eiseman E; Rand Corporation. Case Studies of Existing Human Tissue Repositories: "Best Practices" for a Biospecimen Resource for the Genomic and Proteomic Era. Santa Monica, CA: RAND Corporation; 2003: xxxviii, 208 p.

7. US Department of Health & Human Services. Office for Human Research Protections Web site—regulations on human subjects. http://www.hhs.gov/ohrp/humansubjects/index.html. Accessed July 10, 2014.

8. National Cancer Institute. Office of Biorepositories and Biospecimen Research Web site—NCI best practices for biospecimen resources. http://biospecimens.cancer.gov/bestpractices/. Accessed July 10, 2014.

9. Lehmann S, Guadagni F, Moore H, et al; Betsou International Society for Biological and Environmental Repositories ISBER Working Group on Biospecimen Science F. Standard preanalytical coding for biospecimens: review and implementation of the sample preanalytical code (SPREC). *Biopreserv Biobank.* 2012;10(4):366–374.

10. Moore HM, Kelly A, Jewell SD, et al. Biospecimen reporting for improved study quality. *Biopreserv Biobanking.* 2011;9(1):57–70.

11. Robb JA, Gulley ML, Fitzgibbons PL, et al. A call to standardize preanalytic data elements for biospecimens. *Arch Pathol Lab Med.* 2014;138(4):526–537.

12. ISBER (International Society for Biological and Environmental Repositories). 2012 best practices for repositories: collection, storage, retrieval and distribution of biological materials for research International Society for Biological and Environmental Repositories (ISBER). *Biopreserv Biobank.* 2012; 10(2):81–161.

13. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. *Arch Pathol Lab Med.* 2011;135(5):537–543.

14. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. *Cancer Treat Rev.* 2014;40(2):276–284.

15. Schlomm T, Nakel E, Lubke A, et al. Marked gene transcript level alterations occur early during radical prostatectomy. *Eur Urol.* 2008;53(2):333–344.

16. Freidin MB, Bhudia N, Lim E, Nicholson AG, Cookson WO, Moffatt MF. Impact of collection and storage of lung tumor tissue on whole genome expression profiling. *J Mol Diagn.* 2012;14(2):140–148.

17. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. *J Clin Oncol.* 2006;24(23):3763–3770.

18. Ricciardelli C, Bianco-Miotto T, Jindal S, et al. Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. *Cancer Epidemiol Biomarkers Prev*. 2010;19(7):1755–1765.

19. Bray SE, Paulin FE, Fong SC, et al. Gene expression in colorectal neoplasia: modifications induced by tissue ischaemic time and tissue handling protocol. *Histopathology*. 2010;56(2):240–250.

20. De Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. *BMC Cancer*. 2009;9:409. doi:10.1186/1471-2407-9-409.

21. Barnes RO, Parisien M, Murphy LC, Watson PH. Influence of evolution in tumor biobanking on the interpretation of translational research. *Cancer Epidemiol Biomarkers Prev*. 2008;17(12):3344–3350.

22. Blackhall FH, Pintilie M, Wigle DA, et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. *Neoplasia*. 2004;6(6):761–767.

23. van Maldegem F, de Wit M, Morsink F, Musler A, Weegenaar J, van Noesel CJ. Effects of processing delay, formalin fixation, and immunohistochemistry on RNA recovery from formalin-fixed paraffin-embedded tissue sections. *Diagn Mol Pathol*. 2008;17(1):51–58.

24. Steu S, Baucamp M, von Dach G, et al. A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. *Virchows Arch*. 2008;452(3):305–312.

25. Sewart S, Barraclough R, Rudland PS, West CR, Barraclough DL. Molecular analysis of a collection of clinical specimens stored at 4°C as an alternative to snap-freezing. *Int J Oncol*. 2009;35(2):381–386.

26. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. *Arch Pathol Lab Med*. 2008;132(12):1929–1935.

27. Macabeo-Ong M, Ginzinger DG, Dekker N, et al. Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. *Mod Pathol*. 2002;15(9):979–987.

28. Moelans CB, Oostenrijk D, Moons MJ, van Diest PJ. Formaldehyde substitute fixatives: effects on nucleic acid preservation. *J Clin Pathol*. 2011;64(11):960–967.

29. Gillespie JW, Best CJ, Bichsel VE, et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. *Am J Pathol*. 2002;160(2):449–457.

30. Antonov J, Goldstein DR, Oberli A, et al. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. *Lab Invest*. 2005;85(8):1040–1050.

31. Johnsen IK, Hahner S, Brière JJ, et al. Evaluation of a standardized protocol for processing adrenal tumor samples: preparation for a European adrenal tumor bank. *Horm Metab Res*. 2010;42(2):93–101.

32. Lawson MH, Rassl DM, Cummings NM, et al. Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. *J Thorac Oncol*. 2010;5(7):956–963.

33. Páska C, Bögi K, Szilák L, et al. Effect of formalin, acetone, and RNALater fixatives on tissue preservation and different size amplicons by real-time PCR from paraffin-embedded tissue. *Diagn Mol Pathol*. 2004;13(4):234–240.

34. Botling J, Edlund K, Segersten U, et al. Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. *Diagn Mol Pathol*. 2009;18(1):44–52.

35. Christensen M, Funder AD, Bendix K, Soerensen FB. Comparative investigations of T cell receptor gamma gene rearrangements in frozen and formalin-fixed paraffin wax-embedded tissues by capillary electrophoresis. *J Clin Pathol*. 2006;59(6):645–654.

36. Farrand K, Jovanovic L, Delahunt B, et al. Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. *J Mol Diagn*. 2002;4(3):150–158.

37. Gallegos Ruiz MI, Floor K, Rijmen F, Grunberg K, Rodriguez JA, Giaccone G. *EGFR* and *K-ras* mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. *Cell Oncol*. 2007;29(3):257–264.

38. Talaulikar D, Gray JX, Shadbolt B, McNiven M, Dahlstrom JE. A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. *J Clin Pathol*. 2008;61(1):119–123.

39. Verhoest G, Patard JJ, Fergelot P, et al. Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma. *Urol Oncol*. 2012;30(4):469–475.

40. Solassol J, Ramos J, Crapez E, et al. KRAS mutation detection in paired frozen and formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues. *Int J Mol Sci*. 2011;12(5):3191–3204.

41. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. *Am J Pathol*. 1999;155(5):1467–1471.

42. Kerick M, Isau M, Timmermann B, et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. *BMC Med Genomics*. 2011;4(68).

43. Menon R, Deng M, Boehm D, et al. Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. *Int J Mol Sci*. 2012;13(7):8933–8942.

44. Schweiger MR, Kerick M, Timmermann B, et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. *PLoS One*. 2009;4(5):e5548. doi:10.1371/journal.pone.0005548.

45. Lips EH, Dierssen JW, van Eijk R, et al. Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. *Cancer Res*. 2005;65(22):10188–10191.

46. Thompson ER, Herbert SC, Forrest SM, Campbell IG. Whole genome SNP arrays using DNA derived from formalin-fixed, paraffin-embedded ovarian tumor tissue. *Hum Mutat*. 2005;26(4):384–389.

47. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. *J Invest Dermatol*. 2009;129(5):1219–1224.

48. Turashvili G, Yang W, McKinney S, et al. Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. *Exp Mol Pathol*. 2012;92(1):33–43.

49. Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. *J Clin Pathol*. 2009;62(1):84–88.

50. Szafranska AE, Davison TS, Shingara J, et al. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. *J Mol Diagn*. 2008;10(5):415–423.

51. Benoy IH, Elst H, Van Dam P, et al. Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. *Clin Chem Lab Med*. 2006;44(9):1082–1087.

52. Palmirotta R, De Marchis ML, Ludovici G, et al. Impact of preanalytical handling and timing for peripheral blood mononuclear cells isolation and RNA studies: the experience of the Interinstitutional Multidisciplinary BioBank (BioBIM). *Int J Biol Markers*. 2012;27(2):e90–e98.

53. Liu Y, Malaviarachchi P, Beggs M, Emanuel PD. PTEN transcript variants caused by illegitimate splicing in "aged" blood samples and EBV-transformed cell lines. *Hum Genet*. 2010;128(6):609–614.

54. Birrell GW, Ramsay JR, Tung JJ, Lavin MF. Exon skipping in the ATM gene in normal individuals: the effect of blood sample storage on RT-PCR analysis. *Hum Mutat*. 2001;17(1):75–76.

55. Pahl A, Brune K. Gene expression changes in blood after phlebotomy: implications for gene expression profiling. *Blood*. 2002;100(3):1094–1095.

56. Schoch R, Pitako J, Schafhausen P, et al. Semiquantitative reverse transcription polymerase chain reaction analysis for detection of BCR/ABL rearrangement using RNA extracts from bone marrow aspirates compared with glass slide smears after 0, 2, and 4 d of storage. *Br J Haematol*. 2001;115(3):583–587.

57. Gunther K, Malentacchi F, Verderio P, et al. Implementation of a proficiency testing for the assessment of the preanalytical phase of blood samples used for RNA based analysis. *Clin Chim Acta*. 2012;413(7–8):779–786.

58. Müller MC, Merx K, Weisser A, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. *Leukemia*. 2002;16(120):2395–2399.

59. Kim SJ, Dix DJ, Thompson KE, et al. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profiling of human whole blood. *Clin Chem*. 2007;53(6):1038–1045.

60. Thach DC, Lin B, Walter E, et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. *J Immunol Methods*. 2003;283(1–2):269–279.